Browse > Article

Activities of Natural Plant Extracts against HIV-1  

Eum, Jin-Seong (Division of Bio and Health Sciences, Mokwon University)
Park, Young-Doo (Division of Bio and Health Sciences, Mokwon University)
Hong, Seong-Karp (Department of Microbiology, College of Medicine, The Catholic University of Korea)
Abstract
Anti-HIV-1 activities for the extracts (buthanol, hexane, chloroform, and water) of medicinal plants widely used in the folk medicine were evaluated for screening of anti-AIDS agents. The activities of the extracts to inhibit HIV-1 replication were also analyzed. The 50% effective concentration (EC50) of inhibition activity of the p24 production for chloroform extract of Saphora flavescens, chloroform extract of Herba ephedrae, and hexane extract of Pachyma hoelen Rumph showed 5.8, 29.9, and 37.3 2g/ml, respectively, as good activities. Hexane extract of Sophora flavescens, buthanol extract of Tulipa edulis, hexane extracts of Tulipa edulis, Herba ephedra, and Pachyma hoelen Rumph in the 50% cytotoxic concentration ($CC_{50}$) in inhibition activities of recombinant HIV-1 RT showed 12.9, 19.5, 11.6, 12.0, and 36.8 % at concentration of 200 ${\mu}g$/ml, respectively, as good activities. From these results, chloroform extract of Saphora flavescens, chloroform extract of Herba ephedrae, and hexane extract of Pachyma hoelen Rumph were very effective against HIV-1 among all extracts tested. Therefore, we expect these plants will be a useful for anti- HIV-1 therapeutics in future.
Keywords
Anti-HIV-1; extracts; medicinal plants;
Citations & Related Records
연도 인용수 순위
  • Reference
1 F. Clavel, and A. J. Hance, "HIV drug resistance", N. Engl. J. Med. vol. 350, pp. 1023–1035, 2004   DOI   PUBMED
2 M. J. Ahn, K. D. Yoon, and C. Y. Kim, "Inhibition of HIV-1 reverse transcriptase and HIV-1 integrase and antiviral activity of Korean seaweed extracts", J. Appl. Phycol. vol. 14, pp. 325- 329, 2002   DOI   ScienceOn
3 E. De Clercq, "Current lead natural products for the chemotherapy of human immuno deficiency virus infection", Med. Res. Rev. vol. 20, pp. 323-349, 2000   DOI   PUBMED   ScienceOn
4 C. Tantillo, J. Ding, A. Jacobo-Molina, R. G. Nanni, P. L. Boyer, S. H. Hughes, R. Pauwels, K. Andries, P. A. J. Janssen, and E. Arnold, "Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance", J. Mol. Biol. vol. 243, pp. 369–387, 1994   DOI   PUBMED   ScienceOn
5 J. H.Wang, S.C. Tam, H. Huang, D. Y. Ouyang, Y. Y. Wang, and Y. T. Zheng, "Site-directed PEGylation of trichosanthin retained its anti-HIV activity with reduces potency in vitro", Biochem. Biophys. Res. Commun. vol. 317, pp. 965-971, 2004   DOI   ScienceOn
6 A. J. Vlietinck, T. De Bruyne, S. Apers and L. A. Pieters, "Plant-derived leading compounds for chemotherapy of human immunodeficiency virus (HIV) infection", Planta. Med. vol. 64, pp. 97-109, 1998   DOI   ScienceOn
7 J. J. Lipsky, 'Antiretroviral drugs for AIDS", Lancet vol. 348, pp. 800–803, 1996   DOI   PUBMED   ScienceOn
8 J. M. Kong, N. K. Goh, L. S. Chia, and T. F. Chia, "Recent advances in traditional plant drugs and orchids", Acta. Pharmacol. Sin. vol. 24, pp. 7-21, 2003   PUBMED
9 J. Balzarini, H. Mitsuya, E. De Clercq and S. Broder, "Comparative inhibitory effects of suramin and other selected compounds on the infectivity and replication of human T-cell lymphotropic virus (HTLV-III)/lymphoadenopathy-associated virus (LAV)", Int. J. Cancer. vol. 37, pp. 451–457, 1986   DOI   PUBMED
10 P. S. Sarin, "Molecular pharmacologic approaches to the treatment AIDS", Annu. Rev. Pharmacol. Toxicol. vol. 28, pp. 411–428, 1988   DOI   PUBMED   ScienceOn